Evidence map›Paper›PMID 30070044›Full record

ArticleStem cells translational medicine2018

Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism.

Michael Murias, Samantha Major, Scott Compton, Jessica Buttinger, Jessica M Sun, Joanne Kurtzberg, Geraldine Dawson

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Autologous cord bloodWorld journal of clinical pediatrics · 2025
    Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021
    Review
  18. Article
  19. Digital Behavioral Phenotyping Detects Atypical Pattern of Facial Expression in Toddlers with Autism.Autism research : official journal of the International Society for Autism Research · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael MuriasDuke Institute for Brain Sciences, Duke University, Durham, North Carolina, USA.
Samantha MajorDuke Center for Autism and Brain Development, Duke University, Durham, North Carolina, USA.
Scott ComptonDuke Center for Autism and Brain Development, Duke University, Durham, North Carolina, USA.
Jessica ButtingerDuke Center for Autism and Brain Development, Duke University, Durham, North Carolina, USA.
Jessica M SunRobertson Clinical and Translational Cell Therapy Program, Duke University, Durham, North Carolina, USA.ORCID 0000-0001-8085-1013
Joanne KurtzbergRobertson Clinical and Translational Cell Therapy Program, Duke University, Durham, North Carolina, USA.
Geraldine DawsonDuke Institute for Brain Sciences, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-1410-2764

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was a phase I, single-center, and open-label trial of a single intravenous infusion of autologous umbilical cord blood in young children with autism spectrum disorder (ASD). Twenty-five children between the ages of 2 and 6 with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit were enrolled. Safety results and clinical outcomes measured at 6 and 12 months post-infusion have been previously published. The purpose of the present analysis was to explore whether measures of electroencephalography (EEG) theta, alpha, and beta power showed evidence of change after treatment and whether baseline EEG characteristics were predictive of clinical improvement. The primary endpoint was the parent-reported Vineland adaptive behavior scales-II socialization subscale score, collected at baseline, 6- and 12-month visits. In addition, the expressive one word picture vocabulary test 4 and the clinical global impression-improvement scale were administered. Electrophysiological recordings were taken during viewing of dynamic social and nonsocial stimuli at 6 and 12 months post-treatment. Significant changes in EEG spectral characteristics were found by 12 months post-infusion, which were characterized by increased alpha and beta power and decreased EEG theta power. Furthermore, higher baseline posterior EEG beta power was associated with a greater degree of improvement in social communication symptoms, highlighting the potential for an EEG biomarker to predict variation in outcome. Taken together, the results suggest that EEG measures may be useful endpoints for future ASD clinical trials. Stem Cells Translational Medicine 2018;7:783-791.

Indexed as

Electrophysiological PhenomenaAutism Spectrum DisorderBiomarkersChildChild, PreschoolElectroencephalographyFemaleFetal BloodHumansMaleSocial SkillsTransplantation, AutologousTreatment OutcomeBiomarkersAutologousUmbilical cord blood

Identifiers

PMID30070044
PMCPMC6216432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.